Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CFD | P00746 | 11/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12480155 | 0.85 | KDM4E (0.48) | KDM4ESMN1; SMN2KMT2AALDH1A1LMNA | |
| SCHEMBL12481560 | 0.84 | HSD17B10 (0.61) | KDM4ESMN1; SMN2KMT2AALDH1A1LMNA | |
| SCHEMBL29781847 | 0.84 | HSD17B10 (0.61) | KDM4ESMN1; SMN2KMT2AALDH1A1LMNA | |
| SCHEMBL19236739 | 0.83 | KDM4E (0.46) | KDM4ESMN1; SMN2KMT2AALDH1A1LMNA | |
| SCHEMBL19261506 | 0.82 | KDM4E (0.55) | KDM4ESMN1; SMN2KMT2AALDH1A1LMNA | |
| SCHEMBL17024805 | 0.82 | CFD (0.50) | CFD | |
| SCHEMBL12480168 | 0.82 | MAPT (0.48) | KDM4ESMN1; SMN2KMT2AALDH1A1LMNA | |
| SCHEMBL20488598 | 0.81 | MAPT (0.47) | KDM4ESMN1; SMN2KMT2AALDH1A1LMNA | |
| SCHEMBL15622512 | 0.81 | KDM4E (0.67) | KDM4ESMN1; SMN2KMT2AALDH1A1LMNA | |
| SCHEMBL25097124 | 0.80 | KDM4E (0.43) | KDM4ESMN1; SMN2KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | CFD, TFPI, CFH | KDM4E 4533/4885SMN1; SMN2 3336/4885KMT2A 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.